An open clinical trial of reboxetine in the treatment of social phobia [3]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 4, 2003, Pages 417-419

  Atmaca, Murad ^a   Tezcan, Ertan ^a   Kuloglu, Murat ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE; FLUOXETINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HORMONE RESPONSE; HUMAN; INSOMNIA; LETTER; MALE; MUSCLE WEAKNESS; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SOCIAL PHOBIA; STATISTICAL ANALYSIS; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; MALE; MORPHOLINES; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES;

EID: 0043135269     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000085419.74359.a4     Document Type: Letter

References (18)

1. Kessler RC, Stein MB, Berglund P, et al. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998;155:613-619.
2. Juster HT, Heimberg RG, Holt CS. Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies. Prog Behav Modif. 1996;30:74-98.
3. Gelertner CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatment of social phobia. Arch Gen Psychiatry. 1991;48:938-945.
4. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs. atenolol in social phobia. Arch Gen Psychiatry. 1992;49:290-300.
5. Versiani M, Nardi AE, Mindim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry. 1992;161:353-360.
6. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1995;92:351-358.
7. Noyes JR, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response thai. J Clin Psychopharmacol. 1997;17:247-254.
8. Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998;172:70-77.
9. Stein DJ, Stein MB, Goodwin W, et al. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology. 2001;158:267-272.
10. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156:756-760.
11. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psyhopharmacol. 1988;8:279-283.
12. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull. 1995;31:767-771.
13. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Interview for DSM-III-R (SCID). New York: New York State Psychiatric Institute, Biometrics Research; 1987.
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
15. Liebowitz MR. Social phobia. In: Ban TA, Pichot P, Poldinger W, eds. Modern Problems of Pharmacopsychiatry. Basel: Karger; 1987.
16. Tancer ME, Uhde TW. Neuroendocrine, physiologic, and behavioral responses to clonidine in patients with social phobia. Biol Psychiatry. 1989;25:189.
17. Tancer ME. Neurobiology of social phobia. J Clin Psychiatry. 1993;54:26-30.
18. Goldstein S. Treatment of social phobia with clonidine. Biol Psychiatry. 1987;22:369-372.